Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor–Targeted Therapy-Reference-Cited by-同舟云学术

Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor–Targeted Therapy

Published:2018-08 Issue:4 Volume:16 Page:e927-e933
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Takamatsu Kimiharu,Mizuno Ryuichi,Omura Minami,Morita Shinya,Matsumoto Kazuhiro^ORCID,Shinoda Kazunobu,Kosaka Takeo,Takeda Toshikazu,Shinojima Toshiaki,Kikuchi Eiji^ORCID,Asanuma Hiroshi,Oyama Masafumi,Mikami Shuji,Oya Mototsugu

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference27 articles.

1. Sorafenib in advanced clear-cell renal-cell carcinoma;Escudier;N Engl J Med,2007

2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

3. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma;Hudes;N Engl J Med,2007

4. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008

5. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients;JU Open Plus;2024-04

2. Comprehensive Systematic Review of Biomarkers in Metastatic Renal Cell Carcinoma: Predictors, Prognostics, and Therapeutic Monitoring;Cancers;2023-10-11

3. Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101;ESMO Open;2022-10

4. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor;Urologic Oncology: Seminars and Original Investigations;2022-10

5. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients;Acta Oncologica;2022-07-29